



IFW

ATTORNEY DOCKET NO. 14014.0410U1  
PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of	)	
	)	
Strober, et al.	)	Art Unit: 2123
	)	
Application No. 10/517,898	)	Examiner: Unassigned
	)	
Int'l. Filing Date: June 14, 2002	)	Confirmation No. 5707
	)	
For: "METHODS OF TREATING AND	)	
PREVENTING COLITIS INVOLVING,	)	
IL-13 AND NK-T CELLS"	)	

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.  
Customer Number 36339

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Information Disclosure Statement List is a listing of documents known to Applicants and/or their attorneys. In accordance with 37 C.F.R. §1.98(a)(2), copies of any cited U.S. patent or U.S. patent application publication documents are not enclosed. Copies of any cited foreign patent document and/or any non-patent publication are enclosed.

This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(b)(3), in that a first Office Action on the merits of the present patent application has not yet been mailed to Applicants.

The undersigned hereby certifies that Items C7 and C8 (shown with an \*) recited in the enclosed Supplemental Information Disclosure Statement List were first cited in a


communication from a foreign patent office in a counterpart foreign application (EP 02742057.9-122 ) not more than three months prior to the filing of this Information Disclosure Statement.

Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

No fee is believed due; however, the Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.




Lizette M. Fernandez, Ph.D.  
Patent Agent  
Registration No. 46,694

NEEDLE & ROSENBERG, P.C.  
Customer Number 36339  
(678) 420-9300  
(678) 420-9301 (fax)

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

  
Lizette M. Fernandez, Ph.D.

7/24/07  
Date



(Use as many sheets as necessary)

Complete if Known

Application Number	10/517,898
Filing Date	14 June 2002
First Named Inventor	Warren Strober
Group Art Unit	2123
Examiner Name	Unassigned

[illegible]

Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No
	C1	WO 03/080675	2 Oct 2003	Dunlop et al.	Y
	C2	WO 01/82960	8 Nov 2001	Zeng, D.	Y
	C3	WO 00/64944	2 Nov 2000	Gyure, B	Y

Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)
	C4	Bost et al. "In vivo treatment with anti-interleukin-13 antibodies significantly reduces the humoral immune response against an oral immunogen in mice" <i>Immunol.</i> 87:633-64 (1996)
	C5	Chiaromonte et al. "IL-13 is a key regulator cytokine for Th2 cell-mediated pulmonary granuloma formation and IgE responses induced by <i>S. mansoni</i> eggs" <i>J. Immunol.</i> 162(2):920-930 (1999)
	C6	Grünig et al. "Requirement for IL-13 independently of IL-4 in experimental asthma" <i>Science</i> 282:2261-2263 (18 Dec 1998)
	C7*	Hans et al. "Interleukin 12 induced interferon- $\gamma$ increases inflammation in acute dextran sulfate sodium induced colitis in mice" <i>Eur. Cytokine Netw</i> 11:67-74 (March 2000)
	C8*	Shalaby et al. "In vivo augmentation of natural killer activity by combined treatment with recombinant gamma interferon and Interleukin-2" <i>J Interferon Research</i> 5:571-581 (1985)
	C9	Verdú et al. "Modulatory effects of estrogen in two murine models of experimental colitis" <i>Am J Physiol Gastrointest Liver Physiol</i> 283:G27-G36 (2002)

Examiner Signature:	Date Considered:
---------------------	------------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.